JP2023535815A - 抗血小板薬およびその使用 - Google Patents
抗血小板薬およびその使用 Download PDFInfo
- Publication number
- JP2023535815A JP2023535815A JP2023506150A JP2023506150A JP2023535815A JP 2023535815 A JP2023535815 A JP 2023535815A JP 2023506150 A JP2023506150 A JP 2023506150A JP 2023506150 A JP2023506150 A JP 2023506150A JP 2023535815 A JP2023535815 A JP 2023535815A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- compound
- acceptable salt
- heteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/105513 | 2020-07-29 | ||
| CN2020105513 | 2020-07-29 | ||
| PCT/CN2021/108875 WO2022022559A1 (en) | 2020-07-29 | 2021-07-28 | Antiplatelet drugs and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535815A true JP2023535815A (ja) | 2023-08-21 |
| JP2023535815A5 JP2023535815A5 (https=) | 2024-08-13 |
| JPWO2022022559A5 JPWO2022022559A5 (https=) | 2024-08-13 |
Family
ID=80037185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023506150A Pending JP2023535815A (ja) | 2020-07-29 | 2021-07-28 | 抗血小板薬およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12410132B2 (https=) |
| EP (2) | EP4188935A4 (https=) |
| JP (1) | JP2023535815A (https=) |
| KR (2) | KR102906376B1 (https=) |
| CN (4) | CN119033782B (https=) |
| AR (1) | AR123078A1 (https=) |
| AU (1) | AU2021317436A1 (https=) |
| BR (1) | BR112023001595A2 (https=) |
| CA (1) | CA3186645A1 (https=) |
| ES (1) | ES3046366T3 (https=) |
| IL (1) | IL299979A (https=) |
| MX (1) | MX2023001232A (https=) |
| TW (1) | TW202214609A (https=) |
| WO (1) | WO2022022559A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202339745A (zh) * | 2022-01-28 | 2023-10-16 | 大陸商上海柯君醫藥科技有限公司 | 抗血小板藥物的藥物組合物及其用途 |
| CN116813532A (zh) * | 2023-06-29 | 2023-09-29 | 上海柯君医药科技有限公司 | 一种哌啶化合物的制备方法 |
| WO2025108307A1 (zh) * | 2023-11-24 | 2025-05-30 | 上海柯君医药科技有限公司 | 一种含哌啶环化合物的苯磺酸盐、其制备方法及应用 |
| WO2025108300A1 (zh) * | 2023-11-24 | 2025-05-30 | 上海柯君医药科技有限公司 | 一种含哌啶环化合物的苯磺酸盐的晶型、其制备方法及应用 |
| CN119019320B (zh) * | 2024-10-29 | 2025-03-11 | 上海柯君医药科技有限公司 | 一种具有抗血小板活性的哌啶类化合物的制备方法 |
| CN119176829B (zh) * | 2024-11-26 | 2025-04-15 | 上海柯君医药科技有限公司 | 一种哌啶环化合物的制备方法 |
| CN119192061B (zh) * | 2024-11-28 | 2025-05-13 | 上海柯君医药科技有限公司 | 一种含哌啶环的化合物的纯化方法 |
| CN119371453A (zh) * | 2024-12-30 | 2025-01-28 | 上海柯君医药科技有限公司 | 一种抗血小板药物中间体的制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998008811A1 (en) * | 1996-08-28 | 1998-03-05 | Sankyo Company, Limited | Cyclic amine derivatives |
| CN106554368A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
| CN106554303A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060019929A1 (en) * | 2004-07-07 | 2006-01-26 | Albert Friesen | Combination therapies employing platelet aggregation drugs |
| CN104379589A (zh) * | 2012-05-07 | 2015-02-25 | 塞利克斯比奥私人有限公司 | 抗血小板药剂的前药 |
| KR20150038369A (ko) * | 2012-08-03 | 2015-04-08 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 XIa 억제제로서의 디히드로피리돈 P1 |
| CN103626694A (zh) * | 2012-08-29 | 2014-03-12 | 中国药科大学 | 不饱和环胺衍生物、其制备方法及其医药用途 |
| NO2721243T3 (https=) * | 2014-10-01 | 2018-10-20 | ||
| CN119019320B (zh) * | 2024-10-29 | 2025-03-11 | 上海柯君医药科技有限公司 | 一种具有抗血小板活性的哌啶类化合物的制备方法 |
| CN119192061B (zh) * | 2024-11-28 | 2025-05-13 | 上海柯君医药科技有限公司 | 一种含哌啶环的化合物的纯化方法 |
-
2021
- 2021-07-28 CN CN202410873004.4A patent/CN119033782B/zh active Active
- 2021-07-28 IL IL299979A patent/IL299979A/en unknown
- 2021-07-28 CN CN202411716601.2A patent/CN119552111B/zh active Active
- 2021-07-28 MX MX2023001232A patent/MX2023001232A/es unknown
- 2021-07-28 BR BR112023001595A patent/BR112023001595A2/pt unknown
- 2021-07-28 KR KR1020257016343A patent/KR102906376B1/ko active Active
- 2021-07-28 US US18/018,576 patent/US12410132B2/en active Active
- 2021-07-28 WO PCT/CN2021/108875 patent/WO2022022559A1/en not_active Ceased
- 2021-07-28 ES ES24156405T patent/ES3046366T3/es active Active
- 2021-07-28 EP EP21851193.9A patent/EP4188935A4/en active Pending
- 2021-07-28 CN CN202311275197.5A patent/CN117343000A/zh active Pending
- 2021-07-28 KR KR1020237007048A patent/KR20230047425A/ko active Pending
- 2021-07-28 CA CA3186645A patent/CA3186645A1/en active Pending
- 2021-07-28 CN CN202180058245.8A patent/CN116194459A/zh active Pending
- 2021-07-28 EP EP24156405.3A patent/EP4342532B1/en active Active
- 2021-07-28 AU AU2021317436A patent/AU2021317436A1/en active Pending
- 2021-07-28 JP JP2023506150A patent/JP2023535815A/ja active Pending
- 2021-07-29 AR ARP210102107A patent/AR123078A1/es unknown
- 2021-07-29 TW TW110127818A patent/TW202214609A/zh unknown
-
2025
- 2025-07-08 US US19/262,108 patent/US20250333382A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998008811A1 (en) * | 1996-08-28 | 1998-03-05 | Sankyo Company, Limited | Cyclic amine derivatives |
| CN106554368A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
| CN106554303A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
Non-Patent Citations (12)
| Title |
|---|
| BLUET, GUILLAUME ET AL.: ""Synthesis of the stabilized active metabolite of clopidogrel"", TETRAHEDRON, vol. 70, no. 25, JPN6025023607, 2014, pages 3893 - 3900, ISSN: 0005749009 * |
| DANSETTE, PATRICK M. ET AL.: ""Metabolic Activation of Prasugrel: Nature of the Two Competitive Pathways Resulting in the Opening", CHEMICAL RESEARCH IN TOXICOLOGY, vol. 25, no. 5, JPN6025023605, 2012, pages 1058 - 1065, ISSN: 0005749016 * |
| DELAVENNE, XAVIER ET AL.: ""Ultra‐performance LC MS/MS method for quantification of clopidogrel active metabolite"", JOURNAL OF SEPARATION SCIENCE, vol. 33, no. 13, JPN6025023604, 2010, pages 1968 - 1972, ISSN: 0005749015 * |
| FARID, NAGY A. ET AL.: ""Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chroma", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 21, no. 2, JPN6025023613, 2007, pages 169 - 179, ISSN: 0005749014 * |
| FURLONG, MICHAEL T. ET AL.: ""A validated HPLCMS/MS assay for quantifying unstable pharmacologically active metabolites of clopi", JOURNAL OF CHROMATOGRAPHY B, vol. 926, JPN6025023609, 2013, pages 36 - 41, ISSN: 0005749012 * |
| HAGIHARA, KATSUNOBU ET AL.: ""Glutaredoxin Is Involved in the Formation of the Pharmacologically Active Metabolite of Clopidogre", DRUG METABOLISM AND DISPOSITION, vol. 40, no. 9, JPN6025023611, 2012, pages 1854 - 1859, ISSN: 0005619595 * |
| LIU, CAI ET AL.: ""Development and validation of a sensitive and rapid UHPLCMS/MS method for the simultaneous quantif", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 149, JPN6025023608, 2018, pages 394 - 402, ISSN: 0005749011 * |
| LIU, SHUAI-BING ET AL.: "Determination of clopidogrel and its metabolites in plasma by UPLC-MS/MS and application in pharmaco", YAOWU FENXI ZAZHI, vol. 35, no. 1, JPN6025023606, 2015, pages 56 - 63, ISSN: 0005749018 * |
| SHAW, SCOTT A. ET AL.: ""Synthesis of Biologically Active Piperidine Metabolites of Clopidogrel: Determination of Structure", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 80, no. 14, JPN6025023603, 2015, pages 7019 - 7032, ISSN: 0005749013 * |
| TAKAHASHI, MAKOTO ET AL.: ""Quantitative determination of clopidogrel active metabolite in human plasma by LCMS/MS"", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 48, no. 4, JPN6025023602, 2008, pages 1219 - 1224, ISSN: 0005749010 * |
| TIAN, XI ET AL.: "Determination of clopidogrel and its active metabolite in human plasma by LC-MS/MS", ZHONGGUO YIYAO GONGYE ZAZHI, vol. 47, no. 2, JPN6025023610, 2016, pages 202 - 206, ISSN: 0005749017 * |
| 内田哲郎ら: "(5-Methyl-2-oxo-1,3-dioxol-4-yl) methyl Thiamine Sulfideの合成と性状", 薬学雑誌, vol. 126, no. 3, JPN6025023612, 2006, pages 179 - 186, ISSN: 0005619596 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4188935A4 (en) | 2024-07-17 |
| EP4342532B1 (en) | 2025-09-03 |
| KR20230047425A (ko) | 2023-04-07 |
| US20240279178A1 (en) | 2024-08-22 |
| MX2023001232A (es) | 2023-05-15 |
| EP4342532A2 (en) | 2024-03-27 |
| CN116194459A (zh) | 2023-05-30 |
| EP4342532C0 (en) | 2025-09-03 |
| AU2021317436A1 (en) | 2023-02-23 |
| CA3186645A1 (en) | 2022-02-03 |
| IL299979A (en) | 2023-03-01 |
| US12410132B2 (en) | 2025-09-09 |
| KR102906376B1 (ko) | 2025-12-30 |
| WO2022022559A1 (en) | 2022-02-03 |
| ES3046366T3 (en) | 2025-12-01 |
| CN117343000A (zh) | 2024-01-05 |
| EP4342532A3 (en) | 2024-07-17 |
| KR20250073569A (ko) | 2025-05-27 |
| US20250333382A1 (en) | 2025-10-30 |
| CN119552111B (zh) | 2026-01-02 |
| TW202214609A (zh) | 2022-04-16 |
| CN119033782A (zh) | 2024-11-29 |
| CN119552111A (zh) | 2025-03-04 |
| BR112023001595A2 (pt) | 2023-04-04 |
| EP4188935A1 (en) | 2023-06-07 |
| CN119033782B (zh) | 2025-04-25 |
| AR123078A1 (es) | 2022-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102906376B1 (ko) | 항혈소판 약물 및 이의 용도 | |
| WO2024153119A1 (en) | Kras g12d inhibitors and uses thereof | |
| RU2476430C2 (ru) | Производные аминодигидротиазина, замещенные циклической группой | |
| KR20240087636A (ko) | Kras g12d 억제제 및 이의 용도 | |
| CA3109534A1 (en) | Inhibiting .alpha.v .beta.6 integrin | |
| JP2025081322A (ja) | オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物 | |
| KR20240142492A (ko) | 항혈소판 약물의 약학적 조성물 및 이의 용도 | |
| EP3774736B1 (en) | Compounds as modulators of tlr2 signaling | |
| WO2023125825A1 (en) | Anticoronviral compounds and compositions and uses thereof | |
| RU2841656C1 (ru) | Антитромбоцитарные лекарственные средства и их применение | |
| US11834413B2 (en) | Antiplatelet drugs and uses thereof | |
| HK40117914A (zh) | 抗血小板药物和其用途 | |
| HK40117914B (zh) | 抗血小板药物和其用途 | |
| HK40090099A (zh) | 抗血小板药物和其用途 | |
| CS142991A3 (en) | Alpha-oxopyrrolo/2,3-b/indolacetic acids, their esters, amides and analogs, process for their preparation and their application as medicaments | |
| WO2023138621A1 (en) | Atr inhibitors and uses thereof | |
| WO2026064378A1 (en) | Macrocyclic sulfonamide modulators | |
| WO2025106644A1 (en) | Heterocyclic compounds as inhibitors of alpha-v beta-1 integrin | |
| TW202304910A (zh) | Ｂｃｌ—２或ｂｃｌ—２／ｂｃｌ—ｘｌ之調節劑及其用途 | |
| HK40032239A (en) | Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240726 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240726 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240801 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250617 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250612 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250823 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250916 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260408 |